Table 2.

Non-inferiority comparison of H. pylori eradication rates between the VA and VBQ groups.

Analysis set	VBQ	VA	P-value for superiority	P-value for non-inferiority	Risk difference*
ITT	83.4% (161/193) (95% CI: 78.2%, 88.7%)	82.4% (159/193) (95% CI: 77.0%, 87.8%)	0.787	0.010	-1.04% (95% CI: -8.55%, 6.47%)
mITT	90.4% (161/178) (95% CI: 86.1%, 94.8%)	90.3% (159/176) (95% CI: 86.0%, 94.7%)	0.972	<0.001	-0.11% (95% CI: -6.25%, 6.03%)
PP	90.1% (155/172) (95% CI: 85.7%, 94.6%)	90.5% (153/169) (95% CI: 86.1%, 94.9%)	0.897	<0.001	0.42% (95% CI: -5.86%, 6.69%)

*Risk difference calculated as VA group minus VBQ group. The prespecified non-inferiority margin was -10%. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the risk difference is above -10%.

H. pylori, Helicobacter pylori; VBQ, vonoprazan-bismuth-amoxicillin-doxycycline quadruple therapy; VA, vonoprazan-amoxicillin dual therapy; ITT, intention-to-treat; mITT, modified intention-to-treat; PP, per-protocol.